论文部分内容阅读
目的探讨中小剂量阿奇霉素治疗儿童咳嗽变异性哮喘(CVA)的疗效。方法将2008年1月—2012年1月儿科门诊诊断CVA的患儿150例随机分为3组:A组口服中小剂量阿奇霉素5～7 mg/(kg.d),B组口服孟鲁司特,1～5岁4 mg/d,>5岁5 mg/d;C组吸入布地奈德气雾剂500 ug/d,分1～2次早晚吸入,8岁以下使用储物罐。观察各组的疗效。结果 3组患儿的总有效率分别为94.2%、95.4%、95%差异无统计学意义(P>0.05)。A组患儿和其家长的治疗依从性明显优于B、C两组患儿。结论中小剂量阿奇霉素治疗儿童咳嗽变异性哮喘的临床疗效与吸入布地奈德或口服孟鲁司特无明显差异。
Objective To investigate the effect of small and medium dose azithromycin on children with cough variant asthma (CVA). Methods One hundred and fifty pediatric patients with CVA diagnosed in pediatrics from January 2008 to January 2012 were randomly divided into three groups: group A was treated with small and medium dose azithromycin 5-7 mg / (kg · d), group B was montelukast , 4 mg / d at 1-5 years old, and 5 mg / d at> 5 years old. In group C, inhaled budesonide aerosol 500 ug / d was administered 1 to 2 times a day sooner or later and storage tank below 8 years old. Observed the efficacy of each group. Results The total effective rates of the three groups were 94.2%, 95.4% and 95% respectively, with no significant difference (P> 0.05). Group A children and their parents treatment compliance was significantly better than B, C two groups of children. Conclusion The clinical efficacy of small and medium dose azithromycin in the treatment of children with cough variant asthma and budesonide inhalation or oral montelukast no significant difference.